Aug. 13 at 3:18 PM
$HUM don't overlook
$HAE Q2 results summary below:
Haemonetics (HAE) Q2 CY2025 Highlights:
Revenue:
$321.4 million vs analyst estimates of
$301.6 million (4.4% year-on-year decline, 6.6% beat)
Adjusted EPS:
$1.10 vs analyst estimates of
$1.02 (8.3% beat)
Adjusted EBITDA:
$102.1 million vs analyst estimates of
$93.68 million (31.8% margin, 9% beat)
Management reiterated its full-year Adjusted EPS guidance of
$4.85 at the midpoint
Operating Margin: 16.8%, up from 11.8% in the same quarter last year
Organic Revenue was flat year on year (2.8% in the same quarter last year)
Market Capitalization:
$2.60 billion
